Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs

Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.

Detalles Bibliográficos
Autores principales: Davies, Geraint, Boeree, Martin, Hermann, Dave, Hoelscher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Collection Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615592/
https://www.ncbi.nlm.nih.gov/pubmed/31287813
http://dx.doi.org/10.1371/journal.pmed.1002851
_version_ 1783433378357313536
author Davies, Geraint
Boeree, Martin
Hermann, Dave
Hoelscher, Michael
author_facet Davies, Geraint
Boeree, Martin
Hermann, Dave
Hoelscher, Michael
author_sort Davies, Geraint
collection PubMed
description Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
format Online
Article
Text
id pubmed-6615592
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66155922019-07-25 Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs Davies, Geraint Boeree, Martin Hermann, Dave Hoelscher, Michael PLoS Med Collection Review Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis. Public Library of Science 2019-07-09 /pmc/articles/PMC6615592/ /pubmed/31287813 http://dx.doi.org/10.1371/journal.pmed.1002851 Text en © 2019 World Health Organization http://creativecommons.org/licenses/by/3.0/igo/ Licensee Public Library of Science. This is an open access article distributed under the Creative Commons Attribution IGO License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/3.0/igo/. In any use of this article, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
spellingShingle Collection Review
Davies, Geraint
Boeree, Martin
Hermann, Dave
Hoelscher, Michael
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title_full Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title_fullStr Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title_full_unstemmed Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title_short Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
title_sort accelerating the transition of new tuberculosis drug combinations from phase ii to phase iii trials: new technologies and innovative designs
topic Collection Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615592/
https://www.ncbi.nlm.nih.gov/pubmed/31287813
http://dx.doi.org/10.1371/journal.pmed.1002851
work_keys_str_mv AT daviesgeraint acceleratingthetransitionofnewtuberculosisdrugcombinationsfromphaseiitophaseiiitrialsnewtechnologiesandinnovativedesigns
AT boereemartin acceleratingthetransitionofnewtuberculosisdrugcombinationsfromphaseiitophaseiiitrialsnewtechnologiesandinnovativedesigns
AT hermanndave acceleratingthetransitionofnewtuberculosisdrugcombinationsfromphaseiitophaseiiitrialsnewtechnologiesandinnovativedesigns
AT hoelschermichael acceleratingthetransitionofnewtuberculosisdrugcombinationsfromphaseiitophaseiiitrialsnewtechnologiesandinnovativedesigns

Ejemplares similares